Molecular pathways to high-level azithromycin resistance in Neisseria gonorrhoeae. 2021

J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
Institute of Tropical Medicine, Department of Clinical Sciences, STI Unit, Antwerp, Belgium.

The prevalence of azithromycin resistance in Neisseria gonorrhoeae is increasing in numerous populations worldwide. To characterize the genetic pathways leading to high-level azithromycin resistance. A customized morbidostat was used to subject two N. gonorrhoeae reference strains (WHO-F and WHO-X) to dynamically sustained azithromycin pressure. We tracked stepwise evolution of resistance by whole genome sequencing. Within 26 days, all cultures evolved high-level azithromycin resistance. Typically, the first step towards resistance was found in transitory mutations in genes rplD, rplV and rpmH (encoding the ribosomal proteins L4, L22 and L34 respectively), followed by mutations in the MtrCDE-encoded efflux pump and the 23S rRNA gene. Low- to high-level resistance was associated with mutations in the ribosomal proteins and MtrCDE efflux pump. However, high-level resistance was consistently associated with mutations in the 23S ribosomal RNA, mainly the well-known A2059G and C2611T mutations, but also at position A2058G. This study enabled us to track previously reported mutations and identify novel mutations in ribosomal proteins (L4, L22 and L34) that may play a role in the genesis of azithromycin resistance in N. gonorrhoeae.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009344 Neisseria gonorrhoeae A species of gram-negative, aerobic bacteria primarily found in purulent venereal discharges. It is the causative agent of GONORRHEA. Diplococcus gonorrhoeae,Gonococcus,Gonococcus neisseri,Merismopedia gonorrhoeae,Micrococcus der gonorrhoe,Micrococcus gonococcus,Micrococcus gonorrhoeae
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012338 RNA, Ribosomal, 23S Constituent of 50S subunit of prokaryotic ribosomes containing about 3200 nucleotides. 23S rRNA is involved in the initiation of polypeptide synthesis. 23S Ribosomal RNA,23S rRNA,RNA, 23S Ribosomal,Ribosomal RNA, 23S,rRNA, 23S
D017963 Azithromycin A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. Azadose,Azithromycin Dihydrate,Azithromycin Monohydrate,Azitrocin,Azythromycin,CP-62993,Goxal,Sumamed,Toraseptol,Ultreon,Vinzam,Zentavion,Zithromax,Zitromax,CP 62993,CP62993,Dihydrate, Azithromycin,Monohydrate, Azithromycin
D024881 Drug Resistance, Bacterial The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance, Bacterial,Antibacterial Drug Resistance

Related Publications

J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
April 2015, The Journal of antimicrobial chemotherapy,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
August 2016, The Journal of antimicrobial chemotherapy,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
April 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
August 2009, The Journal of antimicrobial chemotherapy,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
January 2021, Antimicrobial agents and chemotherapy,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
August 1994, Genitourinary medicine,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
September 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
August 1990, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
August 2016, Sexually transmitted infections,
J G E Laumen, and S S Manoharan-Basil, and E Verhoeven, and S Abdellati, and I De Baetselier, and T Crucitti, and B B Xavier, and S Chapelle, and C Lammens, and C Van Dijck, and S Malhotra-Kumar, and C Kenyon
December 2015, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!